Treatment of retinal pigment epithelial detachment with antiangiogenic therapy
Luis AriasDepartment of Ophthalmology, Bellvitge University Hospital, Barcelona, SpainPurpose: Evaluate the efficacy of pegaptanib, a selective anti-vascular endothelial growth factor (VEGF) agent, and bevacizumab, a nonselective anti-VEGF agent, for retinal pigment epithelial detachment (PED) assoc...
Guardado en:
Autor principal: | Luis Arias |
---|---|
Formato: | article |
Lenguaje: | EN |
Publicado: |
Dove Medical Press
2010
|
Materias: | |
Acceso en línea: | https://doaj.org/article/c598f1e30e1748de9e5ed090f0b94d17 |
Etiquetas: |
Agregar Etiqueta
Sin Etiquetas, Sea el primero en etiquetar este registro!
|
Ejemplares similares
-
Efficacy of reduced-fluence photodynamic therapy for serous retinal pigment epithelial detachment with choroidal hyperpermeability
por: Shibata A, et al.
Publicado: (2013) -
Optimizing visualization in enhanced depth imaging OCT in healthy subjects and patients with retinal pigment epithelial detachment
por: Kampik A, et al.
Publicado: (2012) -
Response of serous retinal pigment epithelial detachments to intravitreal aflibercept in polypoidal choroidal vasculopathy refractory to ranibizumab
por: Yamashita M, et al.
Publicado: (2014) -
Bimonthly half-dose ranibizumab in large pigment epithelial detachment and retinal angiomatous proliferation with high risk of retinal pigment epithelium tear: a case report
por: Monés J, et al.
Publicado: (2013) -
Half-dose photodynamic therapy for serous non-neovascular retinal pigment epithelial detachment
por: Inoda S, et al.
Publicado: (2019)